65 related articles for article (PubMed ID: 11363347)
1. Australia reports on AIDS: nef deletions, live vaccines, Chinese travelers.
Mascolini M
J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):6-12, 40. PubMed ID: 11363347
[TBL] [Abstract][Full Text] [Related]
2. 1999: a time to re-evaluate AIDS vaccine strategies.
Ruprecht RM; Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Xu W
J Hum Virol; 2000; 3(2):88-93. PubMed ID: 10850895
[TBL] [Abstract][Full Text] [Related]
3. Attenuated and wild-type HIV-1 infections and long terminal repeat-mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo.
Kent SJ; Cameron PU; Reece JC; Thompson PR; Purcell DF
Virology; 2001 Aug; 287(1):71-8. PubMed ID: 11504543
[TBL] [Abstract][Full Text] [Related]
4. HIV vaccine design: insights from live attenuated SIV vaccines.
Koff WC; Johnson PR; Watkins DI; Burton DR; Lifson JD; Hasenkrug KJ; McDermott AB; Schultz A; Zamb TJ; Boyle R; Desrosiers RC
Nat Immunol; 2006 Jan; 7(1):19-23. PubMed ID: 16357854
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia.
Churchill M; Sterjovski J; Gray L; Cowley D; Chatfield C; Learmont J; Sullivan JS; Crowe SM; Mills J; Brew BJ; Wesselingh SL; McPhee DA; Gorry PR
J Infect Dis; 2004 Dec; 190(12):2181-6. PubMed ID: 15551218
[TBL] [Abstract][Full Text] [Related]
6. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.
Berkhout B; Verhoef K; Marzio G; Klaver B; Vink M; Zhou X; Das AT
J Neurovirol; 2002 Dec; 8 Suppl 2():134-7. PubMed ID: 12491165
[TBL] [Abstract][Full Text] [Related]
7. Immunization for long-term protection against AIDS using the macaque model.
Kumar A; Narayan O
Virology; 2001 Jun; 285(1):1-5. PubMed ID: 11414799
[No Abstract] [Full Text] [Related]
8. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
9. [Linking Nef with the immunological and virological determinants of AIDS].
Gómez-Icazbalceta G; Larralde C
Rev Invest Clin; 2009; 61(3):243-51. PubMed ID: 19736813
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation.
Kent SJ; Dale CJ; Preiss S; Mills J; Campagna D; Purcell DF
J Virol; 2001 Dec; 75(23):11930-4. PubMed ID: 11689679
[TBL] [Abstract][Full Text] [Related]
11. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
[TBL] [Abstract][Full Text] [Related]
12. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
[TBL] [Abstract][Full Text] [Related]
13. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor.
Cohen J
Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780
[No Abstract] [Full Text] [Related]
14. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
15. Reconsidering an attenuated vaccine for AIDS.
Beale J
Lancet; 1996 Feb; 347(8998):344-5. PubMed ID: 8598696
[No Abstract] [Full Text] [Related]
16. Presence of Intact vpu and nef genes in nonpathogenic SHIV is essential for acquisition of pathogenicity of this virus by serial passage in macaques.
Mackay GA; Niu Y; Liu ZQ; Mukherjee S; Li Z; Adany I; Buch S; Zhuge W; McClure HM; Narayan O; Smith MS
Virology; 2002 Mar; 295(1):133-46. PubMed ID: 12033772
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
[TBL] [Abstract][Full Text] [Related]
18. Fifty volunteer for live-vaccine trial.
James JS
AIDS Treat News; 1997 Oct; (No 280):1-2. PubMed ID: 11364735
[TBL] [Abstract][Full Text] [Related]
19. The hunt for the AIDS vaccine.
Essex M
AIDS Asia; 1995; 2(3):10-3. PubMed ID: 12319586
[TBL] [Abstract][Full Text] [Related]
20. Will there be a live-attenuated HIV vaccine available for human safety trials by the year 2000? Interview by Gordon Nary.
Desrosiers RC
J Int Assoc Physicians AIDS Care; 1998 Nov; 4(11):22-3. PubMed ID: 11366120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
